Fallopian Tube Cancers, High-grade Serous Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma
Conditions
Keywords
Ovarian Cancer, High-Grade Serous Ovarian Cancer, PARP Inhibitor, Maintenance Therapy, Dietary Pattern, Low-Carbohydrate Diet
Brief summary
The goal of this retrospective observational study is to evaluate the relationship between different dietary patterns (specifically low-carbohydrate diets) and the prognosis of patients with high-grade serous ovarian cancer (HGSOC) receiving first-line PARP inhibitor (PARPi) maintenance therapy. The main questions it aims to answer are: * Is there an association between dietary patterns and patients' Progression-Free Survival (PFS)? * Is there an association between dietary patterns and Overall Survival (OS)? This is a multicenter, retrospective cohort study. Researchers will review electronic medical records from 14 tertiary hospitals in China to identify women who received first-line PARP inhibitor maintenance for advanced high-grade serous ovarian cancer between 2020 and 2025, and collect information on baseline characteristics, treatments and follow-up outcomes. Researchers will compare patients with a low-carbohydrate diet pattern to those with a regular/high-carbohydrate diet pattern to see if there are differences in treatment outcomes and survival. Participants will: * Have their clinical, pathological, and treatment data collected from electronic medical records. * Complete a retrospective Food Frequency Questionnaire (FFQ) via phone or clinic visit to recall their dietary habits during the maintenance treatment period. * Optionally provide a blood sample for nutrition and metabolic analysis. (For participants at the main study center only) No experimental drugs or specific diets will be given in this study. All anti-cancer treatments are decided by the treating physicians as part of routine clinical care.
Interventions
None listed
Sponsors
West China Second University Hospital
Peking University People's Hospital
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Affiliated Hospital of Qingdao University
Qilu Hospital of Shandong University
Shanghai First Maternity and Infant Hospital
First Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Soochow University
Henan Provincial People's Hospital
The First Affiliated Hospital of Henan University of Science and Technology
Women's Hospital of Zhejiang University
Sun Yat-sen University Cancer Centre
Tongji Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Female patients aged 18 to \<75 years. * Histologically or cytologically diagnosed with primary high-grade serous ovarian cancer (HGSOC), fallopian tube cancer, or primary peritoneal cancer. * Received initial tumor cytoreductive surgery (Primary Debulking Surgery or Interval Debulking Surgery) and first-line platinum-based chemotherapy, achieving Complete Response (CR) or Partial Response (PR). * Received PARP inhibitors as maintenance therapy for the first time following the completion of first-line treatment. * Complete clinical data available in the electronic medical records, including baseline characteristics, first-line treatment details, PARPi maintenance therapy information, and prognostic follow-up data. * The patient (or primary caregiver) has normal communication abilities, voluntarily agrees to participate, and is able to cooperate in completing the retrospective Food Frequency Questionnaire (FFQ).
Exclusion criteria
* Clinical diagnosis only, without pathological or cytological confirmation. * Non-high-grade serous histological subtypes (e.g., ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, low-grade serous carcinoma). * Secondary or metastatic ovarian cancer (malignancy originating from other organs). * Severe deficiency of key clinical or prognostic information that prevents assessment of the primary endpoint. * Inability to accurately recall dietary information due to cognitive impairment, mental illness, or other reasons. * Presence of severe metabolic or digestive system diseases during PARPi maintenance therapy that required specific restricted diets (e.g., insulin-dependent diabetes, dialysis-dependent renal insufficiency, short bowel syndrome, active Crohn's disease). * Occurrence of significant physiological events during the study period that significantly altered dietary structure (e.g., major gastrointestinal surgery).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From the initiation of PARPi maintenance therapy until disease progression or death, assessed up to approximately 60 months (5 years). | PFS is defined as the duration from the start date of PARP inhibitor (PARPi) maintenance therapy to the date of the first documented disease progression or death from any cause, whichever occurs first. Disease progression is assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for radiologic progression or Gynecologic Cancer InterGroup (GCIG) criteria for CA-125 biochemical progression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From the initiation of PARPi maintenance therapy until death, assessed up to approximately 60 months. | OS is defined as the time duration from the start date of PARPi maintenance therapy to the date of death from any cause. For participants who are still alive at the time of data analysis, survival time will be censored at the date of last contact/follow-up. |
| Duration of PARP Inhibitor Maintenance Therapy | From initiation of PARP inhibitor maintenance therapy to permanent discontinuation or last recorded dose, up to 5 years. | Duration of PARP inhibitor (PARPi) maintenance therapy is defined as the time from the date of initiation of PARPi maintenance to the date of permanent discontinuation of PARPi for any reason (including disease progression, adverse events, patient preference, financial reasons, or other clinical decisions). Participants who are still receiving PARPi at the time of analysis will be censored at the date of the last recorded dose. This measure reflects treatment adherence to PARPi maintenance in routine clinical practice. |
| Rate of Treatment Discontinuation Due to Adverse Events | From the initiation of PARPi maintenance therapy to treatment discontinuation, assessed up to approximately 60 months. | The percentage of participants who permanently discontinue PARP inhibitor maintenance therapy specifically due to drug-related adverse events or toxicity. |
Contacts
Primary ContactQinglei Gao, PhD.
Outcome results
None listed